軽度認知症の早期発見へ、新脂質マーカーを開発~将来の診断方法やMCIから認知症への進行診断への応用に期待~

ad

2026-03-23 北海道大学

北海道大学などの研究グループは、軽度認知障害(MCI)の早期発見に向け、血漿・唾液・糞便を対象とした非標的脂質プロファイリングにより新たな脂質バイオマーカーを同定した。LC/MS解析により200種以上の脂質を解析し、特にFA18:3、FA22:5、CE18:2が識別に有効であることを確認。また、糞便中の中鎖脂肪酸含有トリアシルグリセロール(TG-MCFAs)が非侵襲的指標として有望であることを示した。これにより、従来困難だったMCIの早期診断や認知症への進行予測への応用が期待される。

軽度認知症の早期発見へ、新脂質マーカーを開発~将来の診断方法やMCIから認知症への進行診断への応用に期待~
図1.対照群及び軽度認知障害群における複数サンプルの包括的脂質プロファイリング

<関連情報>

脂質オミクスシグネチャーによる軽度認知障害関連バイオマーカーの同定 Lipidomic signatures reveal biomarkers of mild cognitive impairment

Jayashankar Jayaprakash,Siddabasave Gowda B. Gowda,Divyavani Gowda,MiaGB Consortium,Shalini Jain,Hariom Yadav & Shu-Ping Hui
Translational Psychiatry  Published:16 February 2026
DOI:https://doi.org/10.1038/s41398-026-03893-y

Abstract

Mild cognitive impairment (MCI) is an early stage in the progression toward dementia. Lipids are central to neurodegeneration, yet the biomarker potential of lipidomics from saliva, plasma, and feces remains underexplored. As part of the Microbiome in Aging Gut and Brain (MiaGB) consortium, saliva, plasma, and fecal samples were collected from older adults with MCI and healthy controls. Samples were analyzed by high-performance liquid chromatography coupled with high-resolution mass spectrometry (LC/MS), to profile lipidomic alterations and identify candidate biomarkers. Lipidomic profiling annotated over 200 molecular species spanning five major lipid classes. Compared with controls, MCI patients exhibited increased oxidized triacylglycerols (oxTGs) in saliva, reduced cholesteryl linoleate (CE 18:2) in plasma, and decreased fatty acid esters of hydroxy fatty acids (FAHFAs) in feces. Receiver operating characteristic (ROC) analysis identified α-linolenic acid (FA 18:3), docosapentaenoic acid (FA 22:5), and CE 18:2 as discriminatory metabolites with notable diagnostic performance. Moreover, elevated fecal triacylglycerols containing medium-chain fatty acids (TG-MCFAs) were observed in MCI, suggesting impaired lipid absorption or altered metabolism. This multi-sample lipidomics strategy highlights TG-MCFAs as fecal biomarkers for MCI detection, supporting further mechanistic and longitudinal validation.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました